Last reviewed · How we verify
Triptolide-Containing Formulation
Triptolide-containing formulations exert their effects by inhibiting the transcription factor NF-κB, leading to anti-inflammatory and immunosuppressive effects.
Triptolide-containing formulations exert their effects by inhibiting the transcription factor NF-κB, leading to anti-inflammatory and immunosuppressive effects. Used for Rheumatoid arthritis, Systemic lupus erythematosus.
At a glance
| Generic name | Triptolide-Containing Formulation |
|---|---|
| Also known as | Triptolide-Containing Formulation plus standard treatment. |
| Sponsor | Shanghai Changzheng Hospital |
| Drug class | Immunosuppressant |
| Target | NF-κB |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Triptolide, a diterpenoid epoxide, has been shown to suppress the activity of NF-κB, a key transcription factor involved in the regulation of immune responses and inflammation. By inhibiting NF-κB, triptolide-containing formulations can reduce the production of pro-inflammatory cytokines and mediators, leading to anti-inflammatory and immunosuppressive effects. This mechanism of action is thought to contribute to the therapeutic efficacy of triptolide-containing formulations in various diseases.
Approved indications
- Rheumatoid arthritis
- Systemic lupus erythematosus
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |